FDA Commissioner Dr. Marty Makary on New Policy to Combat Industry Influence

New FDA Policy on Advisory Committees

• 🎯 Industry members are being removed from FDA advisory committees to ensure independent scientific evaluation.
• 💡 These members will be replaced, where possible, with patients and family caregivers.
• 🗣️ Pharma companies can still send representatives, but they will be observers who can pose questions, not voting members.

Addressing the "Revolving Door" Problem

• 🚪 The "revolving door" phenomenon, where FDA officials move directly to work for the companies they regulated, is a major concern.
• 💰 This often involves significant salary increases and creates the appearance, if not the reality, of corruption.
• ⚖️ While individuals are free to pursue market-driven opportunities, the FDA aims to prevent undue influence from former regulators.

Combating Perceptions of FDA Capture

• 🤝 The FDA is committed to being user-friendly for industry but must maintain independent scientific evaluation.
• 🇺🇸 The agency belongs to the American people, and efforts are underway to ensure public trust.
• ⚠️ The goal is to prevent situations where drug approvals are based on limited studies, only for the regulator to immediately join the company.

Navigating "The Swamp"

• 📞 Upon nomination, Dr. Makary experienced significant outreach from lobbyists and former members of Congress.
• 🚫 He refused offers of help with his confirmation, emphasizing a desire to avoid obligations to special interests.
• ✅ His confirmation was successful, with bipartisan support, highlighting a non-political approach to the FDA's mission.

Apolitical Work at the FDA

• 🔬 The FDA's work on nutrition guidelines, food ingredients, and infant formula is presented as fundamentally apolitical.
• 📈 Efforts are focused on scientific evaluation and public health, transcending partisan divides.
• 📢 Despite media attempts to spin issues, the focus remains on serving the American people.